CHELMSFORD, Mass., July 24 /PRNewswire/ -- Magellan Biosciences, Inc., an emerging leader in the clinical-diagnostics and biomedical-research markets, announced that Michael E. Woehler, PhD, has been elected to the company's board of directors. From 2001 until February of this year, Dr. Woehler held various senior-executive positions at PAREXEL International Corporation, one of the world's largest contract life-sciences and pharmaceutical-outsourcing organizations, based in Waltham, Massachusetts.
Most recently, Dr. Woehler was PAREXEL's executive vice president, responsible for the company's consulting, medical marketing services, and clinical-pharmacology businesses, as well as corporate services and corporate quality. Previously, he was president of the company's clinical-research services businesses.
"We are on a fast track in the realization of our growth strategy and Mike Woehler will be an important contributor to help navigate the developments ahead," said Magellan President and Chief Executive Officer, Robert J. Rosenthal, PhD. "We plan to expand our portfolio of diagnostic products through new product development and acquisitions that leverage Magellan's expertise in automation, electrochemistry, instrumentation, and regulatory affairs. In addition, we intend to transition our discovery platforms into the clinical arena and partner with biomedical-research customers to commercialize biomarker discoveries into new diagnostic products. Dr. Woehler's expertise in biochemistry, his insight from years of experience in the clinical-diagnostics and life-sciences marketplace, and his proven business acumen will be invaluable as we execute our strategy and help an expanding customer base to improve clinical outcomes."
Prior to PAREXEL, Dr. Woehler was president and chief executive officer of Waltham, Massachusetts-based Mosaic Technologies, Inc., a genomics-platform company with a broad range of patented technologies used for detection, isolation, and purification of nucleic acids. Before that, he spent nearly 20 years in executive positions at Amersham Pharmacia Biotech/Pharmacia Biotech Inc., of Piscataway, New Jersey, a world leader in developing and providing integrated technology platforms for genomic and proteomic research, drug discovery and development, and biopharmaceutical manufacturing.
After receiving a PhD in microbiology/immunology from Marquette University in Milwaukee, Wisconsin, Dr. Woehler was a post-doctoral fellow in the department of biochemistry at the University of Georgia. He also holds a BA in biology/chemistry from Northwestern University in Evanston, Illinois. He began his career at GTE Laboratories, where he was responsible for the exploratory immunology research group.
About Magellan Biosciences
Magellan Biosciences develops point-of-care products, related consumables, and automated laboratory systems for clinical diagnostics and biomedical research worldwide. These tools enable scientists and clinicians to produce better, more-reliable results. And improved results help drive better outcomes: a new understanding of health and disease, earlier, more-accurate diagnoses -- breakthrough discoveries that can lead to novel treatments, new cures -- innovations to enhance life. Magellan serves customers through its wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TekCel. For more information, visit http://www.magellanbio.com.
Magellan Biosciences, Inc.CONTACT: Caroline Grossman for Magellan Biosciences, Inc.,+1-781-771-5579, caroline.grossman@gmail.com
Web site: http://www.magellanbio.com/
